Paradromics
Paradromics is an Invasive Cortical Implants company founded in 2015 and based in Austin, United States. It has raised $53M in total funding, most recently a Series A in 2023.
Builds very-high-density cortical implants targeting tens of thousands of electrodes for speech and communication restoration. Raised $87M in total funding. Connexus Direct Data Interface designed for speech neuroprosthesis; received FDA Breakthrough Device designation in 2023. In February 2025, the NEOM Investment Fund made a strategic investment in Paradromics (amount undisclosed) to build a BCI Center of Excellence; in November 2025 Paradromics received FDA IDE approval for its Connect-One first-in-human study with the Connexus BCI.
Pursuing the highest channel-count roadmap in the invasive space, backed by DARPA funding and private capital, having completed its first-in-human implant in June 2026.
paradromics.com ↗·Invasive Cortical Implants·
United States·private 
